False Negative Report of 18F -FDG PET/CT in a Patient with Liver Metastases due to Uveal Melanoma
Journal of Ophthalmic and Optometric Sciences,
Vol. 5 No. 3 (2021),
15 March 2023
,
Page 37-43
https://doi.org/10.22037/joos.v5i3.40746
Abstract
Background:To report a false negative 18F-Fluorodeoxyglucose (FDG) positron emission tomography/ computed tomography (PET/CT) of liver metastasis in a patient with malignant uveal melanoma.
Material and Methods:A 74-year-old man with left eye uveal melanoma and liver metastasis that was found seven months after the enucleation surgery.
Results:Seven months post-enucleation surgery, ultrasonography revealed a suspicious hepatic lesion. Further investigation using magnetic resonance imaging (MRI) and PET scan was recommended. MRI with and without contrast reported mild post-contrast enhancement in the right lobe of the liver, suggestive of metastasis from the known tumor of the patient. 18F-FDG PET/CT surprisingly showed no metabolic evidence of malignancy throughout the body. Finally, the patient was scheduled for an ultrasound-guided biopsy. Pathology reported metastatic malignant melanoma.
Conclusion:It is important to remember not to rely solely on PET/CT since it may report false negative results in liver metastasis.
- False Negative
- 18F-FDG PET/CT
- Uveal Melanoma
- Liver Metastasis
How to Cite
References
Balasubramanya R, Selvarajan SK, Cox M, Joshi G, Deshmukh S, Mitchell DG, et al. Imaging of ocular melanoma metastasis. The British journal of radiology. 2016;89(1065):20160092.
Chattopadhyay C, Kim DW, Gombos DS, Oba J, Qin Y, Williams MD, et al. Uveal melanoma: from diagnosis to treatment and the science in between. Cancer. 2016;122(15):2299-312.
Crivellaro C, Guglielmo P, De Ponti E, Elisei F, Guerra L, Magni S, et al. 18F-FDG PET/CT in preoperative staging of vulvar cancer patients: is it really effective? Medicine. 2017;96(38).
Chua SC, Groves AM, Kayani I, Menezes L, Gacinovic S, Du Y, et al. The impact of 18 F-FDG PET/CT in patients with liver metastases. European journal of nuclear medicine and molecular imaging. 2007;34:1906-14.
Zhu A, Lee D, Shim H, editors. Metabolic positron emission tomography imaging in cancer detection and therapy response. Seminars in oncology; 2011: Elsevier.
Grassetto G, Fornasiero A, Bonciarelli G, Banti E, Rampin L, Marzola MC, et al. Additional value of FDG-PET/CT in management of “solitary” liver metastases: preliminary results of a prospective multicenter study. Molecular imaging and biology. 2010;12:139-44.
Rabkin Z, Israel O, Keidar Z. Do hyperglycemia and diabetes affect the incidence of false-negative 18F-FDG PET/CT studies in patients evaluated for infection or inflammation and cancer? A comparative analysis. Journal of Nuclear Medicine. 2010;51(7):1015-20.
- Abstract Viewed: 101 times
- pdf Downloaded: 57 times
